Off-label AMD therapies

Article

What are doctors using off-label to treat their AMD patients?

                                       

Avastin (Genentech): Anti-VEGF

Avastin (bevacizumab) is a recombitant humanized, full-length, anti-VEGF monoclonal antibody that binds all isoforms of VEGF-A. Although it is currently only approved for the treatment of colorectal and lung cancer, it is being widely used, off-label, for treatin wet AMD.

In May 2007, the Italian Pharmaceutical Agency (AIFA) announced the reimbursement of Avastin for the treatment of exudative maculopathy and neovascular glaucoma. As such, the agent, which has not been approved for this indication, would be fully reimbursed for use in Italian patients. Click here to read two experts opposing view of this decision.

The manufacturers of Avastin, Genentech, are now trying to prevent the drug being used off-label in the US by restricting sales to independent compounding pharmacies, which divide vials of the drug into smaller portions for use by ophthalmologists. This decision has caused uproar among US retina specialists.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.